SecBot SecBot
Biotech Drug Report Generated Nov 19, 2026

BAXDELA

CRMD·CorMedix Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercialized (first FDA approval June 2017 for ABSSSI; second indication October 2019 for CABP)
Why 4/10
BAXDELA is an already-approved, commercial-stage product with no pending regulatory decision or pivotal readout. It is one of several products in CorMedix's diversified portfolio (acquired via Melinta). The next hard, dated catalyst for CorMedix overall is the REZZAYO sNDA PDUFA (priority review, Q1 2027), not BAXDELA. Per the impact score rubric, an approved drug with no pending binary catalyst scores 3-5; BAXDELA's contribution to the company is moderate, so a 4 is appropriate.
Actionable Insight NEUTRAL

BAXDELA is a mature, already-approved product with no upcoming binary catalyst. The next meaningful catalyst for CorMedix is the REZZAYO sNDA PDUFA (priority review, expected Q1 2027) for prophylaxis of invasive fungal disease, and the closing of the Heron Therapeutics asset acquisition (expected Q1 2027). BAXDELA's contribution to CorMedix's revenue is not separately disclosed but is part of the Melinta portfolio; investors should watch the Q4 2026 earnings for any product-level revenue breakdown.

Price Chart

Loading chart...

Executive Summary

BAXDELA (delafloxacin) is an FDA-approved fluoroquinolone antibiotic for acute bacterial skin and skin structure infections (ABSSSI, approved June 2017) and community-acquired bacterial pneumonia (CABP, approved October 2019). It was originally developed by Melinta Therapeutics, which CorMedix (CRMD) acquired for $300M in September 2025. BAXDELA is one of seven marketed products in CorMedix's portfolio, but it is not the company's lead revenue driver (DefenCath is). As an already-approved, commercial-stage drug with no pending regulatory catalysts, BAXDELA contributes to CorMedix's diversified revenue base but does not represent a binary event for the stock.

How It Works

BAXDELA (delafloxacin) is a fluoroquinolone antibiotic that kills bacteria by interfering with two bacterial enzymes (DNA gyrase and topoisomerase IV) that bacteria need to replicate their DNA. It is available in both intravenous (IV) and oral tablet forms, allowing patients to start treatment in the hospital and transition to pills at home. It is effective against a broad range of Gram-positive, Gram-negative, and atypical bacteria that cause skin infections and pneumonia.

Trial Status

BAXDELA is fully approved by the FDA for two indications: acute bacterial skin and skin structure infections (ABSSSI, approved June 2017) and community-acquired bacterial pneumonia (CABP, approved October 2019). It is commercially available in both IV and oral formulations. No further pivotal trials are underway for BAXDELA.

The Two-Sided Case

▲ Bull Case5
BAXDELA is an FDA-approved antibiotic with two indications (ABSSSI and CABP), providing a steady revenue stream as part of CorMedix's diversified hospital-focused portfolio.
The drug offers interchangeable IV and oral formulations, a convenience advantage that supports hospital formulary adoption and step-down therapy.
CorMedix acquired BAXDELA through the $300M Melinta Therapeutics acquisition in 2025, adding seven marketed products that diversify revenue beyond the lead drug DefenCath.
CorMedix has strong institutional support: American Century, Goldman Sachs, Morgan Stanley, and JPMorgan all added or doubled their positions in Q3 2026, and the CEO and a director made open-market purchases in November 2026 near $4.88-$4.89/share.
Analyst consensus is bullish: 11 Buy/Strong Buy ratings vs 1 Hold, with a mean price target of $13.80 (roughly 205% upside from the current ~$4.55 price).
▼ Bear Case5
BAXDELA is a mature product in a crowded fluoroquinolone antibiotic market with generic competition (levofloxacin, moxifloxacin, ciprofloxacin), limiting its growth potential and pricing power.
CorMedix does not separately disclose BAXDELA product revenue, making it difficult for investors to assess the drug's individual contribution and trajectory within the Melinta portfolio.
CorMedix's Q3 2026 consolidated revenue was only $54.5M (down 48% YoY) due to DefenCath's post-TDAPA pricing transition, and the company reported a net loss of $14.7M, suggesting overall business pressure.
The stock trades near its 52-week low of $4.485 with elevated short-sale volume (z-score 2.82 vs its own history), indicating bearish positioning by some market participants.
The Heron Therapeutics asset acquisition (announced November 2026) adds integration risk and dilution risk (14.58M shares as partial consideration), potentially pressuring the stock.

Upcoming Catalysts

  • REZZAYO (rezafungin) sNDA for prophylaxis of invasive fungal disease: FDA accepted with Priority Review, PDUFA expected in Q1 2027.
  • Closing of Heron Therapeutics asset acquisition (expected Q1 2027), adding four commercial products (ZYNRELEF, APONVIE, CINVANTI, SUSTOL) with ~$125M-$150M in pro forma 2027 revenue.
  • Q4 2026 earnings (expected early 2027) for full-year revenue and product-level performance.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

CorMedix Inc. DEFA14A CRMD ·Originating report

Sources · 8

Hover a chip for the title
1 healio.com2 nasdaq.com3 aafp.org4 fiercepharma.com5 markets.businessinsider.com6 seekingalpha.com7 sec.gov8 sec.gov